OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bekaii-Saab on the Use of Regorafenib in Patients With mCRC

May 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC

May 24th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer

May 24th 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Dr. Simone Discusses the Precision Promise Trial in Pancreatic Cancer

May 23rd 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Dr. Mayor on Neuroendocrine Carcinoma in Gynecologic Tumors

May 23rd 2018

Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

Dr. Perl on Remaining Challenges with CAR T-Cell Therapy

May 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses remaining challenges with chimeric antigen receptor (CAR) T-cell therapy.

Dr. McGregor on New Combinations With Immunotherapy in RCC

May 23rd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

May 23rd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer

May 23rd 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.

Dr. Newman on Advances in Axillary Surgery in Breast Cancer

May 22nd 2018

Lisa A. Newman, MD, director, Breast Oncology Program, Henry Ford Cancer Institute, discusses advances in axillary surgery for the treatment of patients with node-positive breast cancer.

Dr. Simon on Genomic Assays for Patients With Breast Cancer

May 22nd 2018

Michael Simon, MD, MPH, medical oncologist, Karmanos Cancer Institute, discusses genomic assays for patients with breast cancer.

Dr. Gold on the Future of Osimertinib in Lung Cancer

May 22nd 2018

Kathryn A. Gold, MD, associate professor of medicine, University of California, San Diego, discusses the future of osimertinib (Tagrisso) in the treatment of patients with EGFR-mutant lung cancer.

Dr. Ramanathan on Emerging Therapeutic Targets in Patients With Pancreatic Cancer

May 22nd 2018

Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses emerging therapeutic targets in patients with pancreatic cancer.

Dr. O'Neil on Neuroendocrine Tumors

May 22nd 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Dr. Baker on the Importance of Symptom Management in Children With Cancer

May 22nd 2018

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses the importance of symptom management in children with cancer.

Dr. Walker on the Use of Radiation Therapy in Patients With Breast Cancer

May 22nd 2018

Eleanor M. Walker, MD, senior staff physician, division director, Breast Services in the Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.

CDK4 Inhibition With Palbociclib in MCL

May 22nd 2018

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

Dr. Sznol Discusses the Importance of Clinical Trials in RCC

May 22nd 2018

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.

Dr. Ali on Choosing Adjuvant Treatment for HER2+ Breast Cancer

May 18th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the adjuvant treatment of patients with HER2-positive breast cancer.

Dr. Harshman on Earlier Use of Immunotherapy in RCC

May 18th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).